Loading
A phase 1/2 trial of Oxaliplatin, Capecitabine and Leucovorin (folinic acid) in advanced solid tumours, run by Zhejiang Doer Biologics Co., Ltd., now recruiting.
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer is a phase 1/2 interventional study registered as NCT07056777 by Zhejiang Doer Biologics Co., Ltd., with 186 participants planned, started 2025-03-25 and due to reach its primary completion in 2027-04-30. Interventions recorded: DR30206, Oxaliplatin, Capecitabine, Calcium Folinate, 5-FU and Irinotecan (CPT-11).
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Leucovorin (folinic acid), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.